Q3 2026 13F filing
Updated 10 days ago82 disclosed positions worth $182.8M
Full holdings
Every line item disclosed in Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | G Alphabet Inc-Cl C | $31.1M | 91.2K | 17.00% | — |
| 2 | A Apollo Global Management, Inc. | $26.1M | 225.0K | 14.28% | — |
| 3 | J Iovance Biotherapeutics, Inc. | $17.3M | 1.17M | 9.44% | — |
| 4 | X Xeris Biopharma Holdings, Inc. | $9.6M | 1.00M | 5.24% | — |
| 5 | S Syndax Pharmaceutical, Inc. | $8.1M | 428.3K | 4.40% | — |
| 6 | T Travere Therapeutics, Inc. | $7.7M | 130.0K | 4.19% | — |
| 7 | B Bridgebio Pharma, Inc. | $6.6M | 100.0K | 3.60% | — |
| 8 | J JPMorgan Chase & Co. | $5.8M | 17.4K | 3.15% | — |
| 9 | L LPL Financial Holdings Inc. | $5M | 16.5K | 2.76% | — |
| 10 | N Janus Henderson AAA CLO ETF | $4.7M | 93.5K | 2.58% | — |
| 11 | A Alkermes PLC | $4.6M | 114.5K | 2.54% | — |
| 12 | P Protagonist Therapeutics, Inc | $4.6M | 32.7K | 2.52% | — |
| 13 | H Cybin Inc | $4.5M | 370.0K | 2.49% | — |
| 14 | C Cogent Biosciences Inc. | $4.4M | 136.1K | 2.38% | — |
| 15 | V Viridian Therapeutics, Inc. | $3.9M | 191.0K | 2.15% | — |
| 16 | T TG Therapeutics, Inc. | $3.3M | 59.8K | 1.83% | — |
| 17 | R Arcus Biosciences, Inc. | $2.6M | 100.2K | 1.42% | — |
| 18 | M Madrigal Pharmaaceuticals, Inc. | $1.8M | 3.6K | 0.99% | — |
| 19 | R Relmada Therapeutics, Inc. | $1.8M | 480.0K | 0.99% | — |
| 20 | S SPDR S&P Biotech ETF | $1.7M | 11.0K | 0.95% | — |
| 21 | A AllianceBernstein Holding L.P. | $1.7M | 48.0K | 0.92% | — |
| 22 | M Agios Pharmaceutical, Inc. | $1.6M | 49.1K | 0.89% | — |
| 23 | O Orchestra Biomed Holdings, Inc. | $1.6M | 253.7K | 0.86% | — |
| 24 | C Cullinan Therapeutics, Inc. | $1.5M | 95.4K | 0.80% | — |
| 25 | C CareDx, Inc. | $1.4M | 22.2K | 0.79% | — |
| 26 | E Enliven Therapeutics, Inc. | $1.3M | 28.9K | 0.72% | — |
| 27 | S Spruce Biosciences, Inc. | $1.3M | 26.1K | 0.69% | — |
| 28 | C Eldgridge BBB-B | $1.3M | 47.8K | 0.69% | — |
| 29 | D DocGo, Inc. | $1.1M | 2.67M | 0.58% | — |
| 30 | P Pfizer Inc. | $922K | 32.3K | 0.50% | — |
| 31 | O Oruka Therapeutics, Inc. | $916K | 11.0K | 0.50% | — |
| 32 | C Collegium Pharmaceutical, Inc. | $851K | 39.0K | 0.47% | — |
| 33 | D Dyne Therapeutics, Inc. | $838K | 52.0K | 0.46% | — |
| 34 | A Apple Inc. | $831K | 2.5K | 0.45% | — |
| 35 | M Microsoft Corporation | $821K | 1.6K | 0.45% | — |
| 36 | R Rezolute, Inc. | $661K | 159.6K | 0.36% | — |
| 37 | C Canadian Natural Resources Limited | $655K | 13.9K | 0.36% | — |
| 38 | L LB Pharmaceuticals, Inc. | $655K | 17.1K | 0.36% | — |
| 39 | J Johnson & Johnson | $529K | 2.0K | 0.29% | — |
| 40 | E iShares Biotechnology ETF | $526K | 2.5K | 0.29% | — |
| 41 | S Solid Bioscience Inc. | $514K | 71.1K | 0.28% | — |
| 42 | D DuPont de Nemours, Inc. | $489K | 3.8K | 0.27% | — |
| 43 | I International Business Machines | $471K | 2.1K | 0.26% | — |
| 44 | C Connect Biopharma Holdings Limited | $462K | 419.9K | 0.25% | — |
| 45 | B Biogen Inc. | $452K | 2.0K | 0.25% | — |
| 46 | E Edgewise Therapeutics, Inc. | $426K | 10.5K | 0.23% | — |
| 47 | P Pelthos Therapeutics, Inc. | $371K | 17.6K | 0.20% | — |
| 48 | N Nvidia Corp | $292K | 1.3K | 0.16% | — |
| 49 | R Ryman Hospitality Properties, Inc. | $287K | 2.4K | 0.16% | — |
| 50 | I Insmed Incorporated | $257K | 2.3K | 0.14% | — |